We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Celera Acquires Interest in HuBit Genomix

By Labmedica staff writers
Posted on 30 Mar 2001
An agreement to acquire a minority interest in Hubit Genomix, Inc. (Tokyo, Japan), an emerging biotechnology company, has been announced by Celera Genomics (Rockville, MD, USA). Financial terms were not disclosed.

Hubit Genomix is focused on the discovery and association of genes, particularly single nucleotide polymorphisms (SNPs), for use in the development of therapeutics and diagnostics. The company plans to provide its biologic information to pharmaceutical, biotechnology companies, and research centers. Celera, an operating group of Applera Corp., has developed an online information business and other services based on its generation, integration, and analysis of biologic information.

"This agreement represents an important opportunity for both companies, since it should allow HuBit to expand its research and development in analyzing genetic variation, potentially involving Celera as a business and scientific partner in these important areas,” said J. Craig Venter, Ph.D, president and chief scientific officer of Celera.



Related Links:
Celera Genomics

New
Gold Member
Automated Clinical Chemistry Analyzer
Envoy 500+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
3-Part Hematology Analyzer
Medonic M32C
New
Total Laboratory Automation Solution
SATLARS Mini T8

Latest Industry News

Integrated DNA Technologies Expands into Clinical Diagnostics
30 Mar 2001  |   Industry

Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
30 Mar 2001  |   Industry

Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
30 Mar 2001  |   Industry



INTEGRA BIOSCIENCES AG